Drugs and devices synergy: a new session focus at EuroPCR!
Understanding and delivering the best pharmacological care in patients treated with devices
At a time when pharmacological and interventional resources have become so numerous and varied, there is a myriad of possibilities in terms of drug selection, combination, timing of initiation, dosing and duration.
Not all of these combinations can be tested, guidelines cannot address their diversity, and evidence is often unavailable, partial, or very complex and confusing. Clinicians therefore quite frequently have to rely on their best clinical judgement.
New this year at EuroPCR, a special focus on drugs and devices synergy will help participants to see clearer in the constantly evolving field of pharmacology. In particular, the following four case-based educational sessions which were initiated by a specialist in the field, P.G. Steg. These sessions will see the indicated leading interventionist address a dilemma in the field of drug-device interactions:
The Drugs and devices synergy programme at EuroPCR 2018 includes four case-based collaborative sessions, devoted to addressing a single common clinical conundrum in the field of drug-device interactions. These sessions, involving recognised international experts, will lead to a simple “PCR clinical algorithm”, endorsed by each expert and build in co-operation with the audience. PCR clinical algorithms will be made available via PCRonline to the entire interventional community shortly after the session.